These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 15515031)

  • 41. Cardiac surgery in a patient with retroperitoneal fibrosis and heart valvulopathy, both due to pergolide medication for Parkinson's disease.
    Apostolakis EE; Baikoussis NG; Tselikos D; Koniari I; Prokakis C; Fokaeas E; Karanikolas M
    J Cardiothorac Surg; 2009 Nov; 4():65. PubMed ID: 19912629
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Valvular health disease with pergolide.
    Prescrire Int; 2003 Dec; 12(68):225. PubMed ID: 14986695
    [No Abstract]   [Full Text] [Related]  

  • 43. Dopamine agonists and valvular heart disease.
    Cheung D; Heaney A
    Curr Opin Endocrinol Diabetes Obes; 2009 Aug; 16(4):316-20. PubMed ID: 19506475
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The risk of valvular regurgitation in patients with Parkinson's disease treated with dopamine receptor agonists.
    Rasmussen VG; Østergaard K; Dupont E; Poulsen SH
    Mov Disord; 2011 Apr; 26(5):801-6. PubMed ID: 21671508
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Dopamine agonists and valvular heart disease.
    Sartiani L; Cerbai E; Mugelli A
    N Engl J Med; 2007 Apr; 356(16):1677-8; author reply 1678-80. PubMed ID: 17447276
    [No Abstract]   [Full Text] [Related]  

  • 46. Medical hazards of the internet: gambling in Parkinson's disease.
    Larner AJ
    Mov Disord; 2006 Oct; 21(10):1789. PubMed ID: 16941457
    [No Abstract]   [Full Text] [Related]  

  • 47. [Impulse control disorder induced by the use of dopamine agonists].
    Weber WE; Nijssen PC
    Ned Tijdschr Geneeskd; 2009 Jan; 153(3):80-1. PubMed ID: 19235343
    [No Abstract]   [Full Text] [Related]  

  • 48. Valvular heart disease in patients with Parkinson's disease treated with pergolide, levodopa or both.
    Ozer F; Tiras R; Cetin S; Ozturk O; Aydemir T; Ozben S; Meral H; Kizkin S; Bader H; Ozben B
    J Clin Neurosci; 2009 Jan; 16(1):83-7. PubMed ID: 19014887
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Nocturnal activity with nighttime pergolide in Parkinson disease: a controlled study using actigraphy.
    Comella CL; Morrissey M; Janko K
    Neurology; 2005 Apr; 64(8):1450-1. PubMed ID: 15851743
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Pergolide-induced lung disease in patients with Parkinson's disease.
    Kastelik JA; Aziz I; Greenstone MA; Thompson R; Morice AH
    Respir Med; 2002 Jul; 96(7):548-50. PubMed ID: 12194642
    [No Abstract]   [Full Text] [Related]  

  • 51. Diagnosis and management of pergolide-induced fibrosis.
    Agarwal P; Fahn S; Frucht SJ
    Mov Disord; 2004 Jun; 19(6):699-704. PubMed ID: 15197712
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Pergolide-induced pleuropulmonary fibrosis.
    Bleumink GS; van der Molen-Eijgenraam M; Strijbos JH; Sanwikarja S; van Puijenbroek EP; Stricker BH
    Clin Neuropharmacol; 2002; 25(5):290-3. PubMed ID: 12410064
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Drug-induced valvular heart disease].
    Blaschke D; Rolf S; Parwani AS; Huemer M; Dietz R; Garbe E; Haverkamp W
    Dtsch Med Wochenschr; 2009 Feb; 134(8):365-70. PubMed ID: 19206055
    [No Abstract]   [Full Text] [Related]  

  • 54. Risk of valvular heart disease associated with the use of dopamine agonists in Parkinson's disease: a systematic review.
    Steiger M; Jost W; Grandas F; Van Camp G
    J Neural Transm (Vienna); 2009 Feb; 116(2):179-91. PubMed ID: 19142570
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Fibrotic valvular heart disease subsequent to bromocriptine treatment.
    Serratrice J; Disdier P; Habib G; Viallet F; Weiller PJ
    Cardiol Rev; 2002; 10(6):334-6. PubMed ID: 12390688
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Pergolide-induced dyspnea, bilateral pleural effusion and peripheral edema.
    Varsano S; Gershman M; Hamaoui E
    Respiration; 2000; 67(5):580-2. PubMed ID: 11070468
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Rounded atelectasis and respiratory compromise secondary to pergolide use.
    Bloom CI; Wilson GE
    Respirology; 2009 Aug; 14(6):906-7. PubMed ID: 19659834
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Retroperitoneal fibrosis caused by pergolide in a patient with Parkinson's disease.
    Bilici A; Karadag B; Doventas A; Erdincler DS; Cetinkaya S; Ogut G; Tezcan V; Beger T
    Neth J Med; 2004 Nov; 62(10):389-92. PubMed ID: 15683095
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Drug-induced valve heart disease].
    Tribouilloy C; Jobic Y
    Rev Prat; 2016 Oct; 66(8):874-880. PubMed ID: 30512542
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Pergolide-induced pleural effusion in a patient with juvenile parkinsonism].
    Kuwabara T
    Rinsho Shinkeigaku; 2002 Aug; 42(8):757-60. PubMed ID: 12701223
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.